Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems

Jan 28, 2008, 00:00 ET from Clontech Laboratories, Inc.

    MOUNTAIN VIEW, Calif., Jan. 28 /PRNewswire/ -- Clontech Laboratories,
 Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the
 imminent (February 20, 2008) release of its ProteoTuner systems, which will
 be featured in the April issue of Clontechniques, the company's quarterly
 newsletter. Based on work by researchers at Stanford University and
 licensed from Stanford, the ProteoTuner systems use a unique technology to
 regulate the amount of protein of interest present in a cell, quickly and
 directly. This new technique enables direct manipulation of the in vivo
 level of a specific protein of interest, making it a powerful tool for
 analyzing protein function. Because the system has very low toxicity, it is
 also suitable for animal studies.
     "As a long-standing leader in the field of gene expression control,
 Clontech is proud to add the ProteoTuner systems to its extensive
 collection of gene and protein control systems, which include the Tet-On(R)
 Advanced and Tet-Off(R) Advanced Inducible Gene Expression systems for gene
 expression control and the Knockout(TM) RNAi systems for mRNA knockdown.
 Each of these three systems has particular, complementary strengths: the
 tight regulation of the Tet systems, Knockout RNAi's excellent control of
 endogenous protein levels, and the fast control of protein levels via the
 ProteoTuner systems. Each can be used independently or combined to enable
 exquisite control over protein expression," said Carol Lou, General Manager
 of Clontech Laboratories, Inc.
     Clontech's ProteoTuner systems have broad applications in basic and
 applied research. The fast kinetics of protein
 stabilization/destabilization make it possible to study transient effects
 of the protein of interest that might otherwise have been masked. The
 ability to directly control the level of functional protein also makes this
 technology an unprecedented tool for dissecting the roles of
 multifunctional proteins, by directly and specifically "tuning" the level
 of a protein of interest in the cell. Thus, the ProteoTuner systems offer a
 unique new resource: the ability to directly regulate protein levels
 without affecting the normal translational and transcriptional activities
 of the gene of interest.
     About Clontech Laboratories, Inc.
     Clontech Laboratories, Inc. develops, produces, and markets
 leading-edge biological products to the life science market worldwide.
 Clontech has approximately 2,000 products that enable life science
 researchers to study genes, their products, and their cellular function
 through the use of innovative and powerful tools for gene cloning,
 labeling, and expression; as well as for elucidating protein:protein
 interactions; isolating and purifying DNA and proteins; and conducting a
 wide variety of PCR experiments. Clontech is a wholly-owned subsidiary of
 Takara Bio Inc. For more information visit
     About Takara Bio Inc.
     Takara Bio Inc. is an innovative biotechnology company based in Shiga,
 Japan. As a world leader in biotechnology research and development, Takara
 Bio was the first company to market PCR technology in Japan and is also the
 developer of the RetroNectin(R) reagent, which is a world-standard in gene
 therapy protocols. In addition to providing research reagents and equipment
 to the life science research market, Takara Bio has active research and
 product development activities in the fields of gene and cell-based
 therapy, and agricultural biotechnology; and is committed to preventing
 disease and improving the quality of life for all people through the use of
 biotechnology. Through strategic alliances with other industry leaders, the
 Company aims to extend its reach around the world. More information is
 available at

SOURCE Clontech Laboratories, Inc.